


We claim:

1. A compound, having a formula




- 5 or a pharmaceutically acceptable salt thereof, wherein:

ring B is 5-membered or 6-membered heteroaryl;

L is a heteroatom or Rᵃ, provided that Rᵃ is not H or D;

Z is C₁-₁₀ aliphatic (such as C₁-₁₀ alkyl, C₂-₁₀ alkenyl, C₂-₁₀ alkynyl, or C₃-₆ cycloalkyl); or



- 10 R¹ is a halogen, -C≡CH, or a -linker-R⁶ group, wherein the linker is Rᵃ, provided that Rᵃ is not H or D, and R⁶ is Rᵇ, -C(Rᶠ)₃, or -C(Rᶠ)=C(Rᶠ)₂;

R² and R³ independently are Rᵃ;

R⁴ and R⁵ independently are Rᵉ;

Rᵃ is independently for each occurrence H, D, C₁-₁₀ aliphatic, C₁-₁₀ haloaliphatic, C₅-₁₀ aromatic, or

- 15 C₃-₆ heterocyclic;

Rᵇ is independently for each occurrence -OH, -SH, -ORᶜ, -SRᶜ, -NRᵈRᵈ, -Si(Rᵃ)₃, -C(O)OH, -C(O)ORᶜ, or -C(O)NRᵈRᵈ;

Rᶜ is independently for each occurrence C₁-₁₀ alkyl, C₂-₁₀ alkenyl, C₂-₁₀ alkynyl, C₃-₆ cycloalkyl, or C₅-₁₀ aromatic;

- 20 Rᵈ is independently for each occurrence H; C₁-₆ alkyl; C₃-₆ cycloalkyl; C₃-₆ heterocyclic; C₅-₁₀ aryl; C₅-₁₀ heteroaryl; or two Rᵈ groups together with the nitrogen bound thereto provide a C₃-₉ heterocyclic, or a C₅-₁₀ heteroaryl;

Rᵉ is independently for each occurrence halogen, C₁-₆ alkyl, C₂-₁₀ alkenyl, C₂-₁₀ alkynyl, C₁-₆ haloalkyl, C₃-₆ cycloalkyl, C₅-₁₀ heteroaryl, or -ORᵃ;

- 25 Rᶠ is independently for each occurrence Rᵃ, Rᵇ, or Rᶜ, or two Rᶠ groups together with the carbon atom bound thereto provide a C₃-₆ cycloalkyl group, or a C₃-₁₀ heterocyclic;


m is 1 to 4;

n is 0, 1 or 2; and


p is 0, 1, 2, 3, 4, or 5.

30

2. The compound of claim 1, wherein the compound has a formula




3. The compound claim or claim 2, wherein the compound has a structure satisfying a formula



- 5 wherein L is oxygen or CH₂.


4. The compound of any one of claims 1-3, wherein ring B has a structure satisfying a




10

5. The compound of any one of claims 1-4, wherein ring B is a diazole, a triazole, an oxadiazole, an oxazole, or a pyridinyl.


6. The compound of claim 5, wherein the triazole is




- 15 the diazole is



- the oxadiazole is



- the oxazole is



7. The compound of any one of claims 1-6, wherein R^5 is R^e , wherein R^e is halogen or methyl.

8. The compound of any one of claims 1-7, wherein the linker of the linker- R^6 group is R^a

5 wherein R^a is a C_1 , C_2 , C_3 , or C_4 aliphatic group comprising an alkyl, alkenyl, or alkynyl group.

9. The compound of claim 8, wherein the C_2 group comprises an alkyne and wherein R^6 is R^b wherein R^b is $-C(R^f)_3$, wherein one R^f is R^e and each other R^f independently for each occurrence is R^a , wherein R^a is C_{1-4} alkyl.



10

10. The compound of claim 9, wherein R^e is $-OR^a$, wherein R^a is H.


11. The compound of claim 9 or claim 10, wherein R^a is methyl.


15

12. The compound of any one of claims 9-11, wherein ring B is




13. The compound of any one of claims 1-12, wherein R^1 is







14. The compound of any one of claims 1-13, wherein the compound is




I-1;




I-2;




I-3;




I-4;




I-5;




I-6;




I-7;




I-8;




I-9;




I-10;




I-11;




I-12;




I-13;




I-14;




I-15;




I-16;




I-17;




I-18;




I-19;




I-20;




I-21;




I-22;




I-23;




I-24;




I-25;




I-26;




I-27;




I-28;




I-29;




I-30;




I-31;




I-32;




I-33;




I-34;




I-35;




I-36;




I-37;




I-38;




I-39;




I-40;




I-41;




I-42;




I-43;




I-45;




I-47;




I-49;




I-51;




I-53;




I-55;




I-44;




I-46;




I-48;




I-50;




I-52;




I-54;




I-56;




I-57;




I-58;




I-59;




I-60;




I-61;




I-62;




I-63;




I-64;




I-65;




I-66;




I-67;




I-68;




I-69;




I-70;




I-71;




I-72;




I-73;




I-74;




I-75;




I-76;




I-77;




I-78;




I-79;




I-80;




I-81;




I-82;




I-83;




I-84;




I-85;




I-86;




I-87;




I-88;




I-89;




I-90;




I-91;




I-92;




I-93;




I-94;



I-95;





I-96; or



I-97.

15. The compound of any one of claims 1-14, wherein the compound is





16. A pharmaceutical composition, comprising a compound according to any one of claims 1-15, an excipient, a therapeutic agent, or combinations thereof.


5

17. A method, comprising contacting a receptor-interacting protein-1 (RIP1) kinase with a compound according to any one of claims 1-15, or a pharmaceutical composition according to claim 16.

18. A method for treating a disease in a subject, comprising administering to the subject (i) a therapeutically effective amount of the compound of any one of claims 1-15, or a pharmaceutically acceptable salt, a stereoisomer, an N-oxide, a tautomer, a hydrate, a solvate, an isotope, or a prodrug thereof; or (ii) a therapeutically effective amount of a pharmaceutical composition of claim 16; wherein the subject has, or is suspected of having or developing, the disease, wherein the disease is a disease involving a receptor-interacting protein-1 (RIP1) kinase.

15

19. The method of claim 17 or claim 18, wherein the compound is




20

20. A method for making the compound of any one of claims 1-15, comprising:
coupling a starting material having a Formula A with an R^1 -containing reagent, by combining the starting material and the R^1 -containing reagent, wherein R^1 comprises a linker- R^6 group, with a transition metal catalyst, a base, and a solvent to form a functionalized product;
deprotecting an amine group of the functionalized product to provide an amine compound; and
forming an amide bond between the amine compound and an acid-containing coupling partner to provide an amide-containing compound;


25

wherein Formula A is




Formula A;

the functionalized product has a structure satisfying Formula B



Formula B;

and the acid-containing coupling partner has a structure satisfying Formula C



Formula C; and wherein

X is a halogen or a triflate;

PG is an amine protecting group;

and each of ring B, L, R¹, R², R⁴, R⁵, m, n, and p are as recited for any one of claims 1-15.